{
    "clinical_study": {
        "@rank": "58872", 
        "acronym": "FAVOR", 
        "arm_group": [
            {
                "arm_group_label": "Treatment sequence 1", 
                "arm_group_type": "Experimental", 
                "description": "QVA149 from day 1 to day 28 and tiotropium from day 29 to day 56"
            }, 
            {
                "arm_group_label": "Treatment sequence 2", 
                "arm_group_type": "Experimental", 
                "description": "Tiotropium from day 1 to day 28 and QVA149 from day 29 to day 56"
            }
        ], 
        "brief_summary": {
            "textblock": "The study is a multicenter, randomized, 2-period, open-label, two arm, cross-over study to\n      show the superior effect of a 4 week treatment each with QVA149  versus tiotropium on lung\n      function. Similarly, this study aims to evaluate patient preference after experiencing both\n      treatment regimens in patients with a clinical diagnosis of COPD (GOLD 2013) and a moderate\n      to severe airflow limitation who are symptomatic (defined as CAT score of at least 10) at\n      screening despite being treated with tiotropium"
        }, 
        "brief_title": "Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Obstructive Pulmonary Disease", 
            "COPD"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  signed an Informed Consent Form\n\n          -  stable COPD according to current guidelines (GOLD 2013)\n\n          -  airflow limitation indicated by a post-bronchodilator FEV1/FVC ratio of <0.70 and a\n             post-bronchodilator FEV1 of \u226530% and <80% of predicted normal values at Visit 2.\n\n          -  current or ex-smokers who have a smoking history of at least 10 pack years\n\n          -  Patients on stable tiotropium (18 \u00b5g/d) monotherapy for at least 8 weeks before Visit\n             1\n\n          -  Symptomatic patients defined as patients with CAT score \u2265 10 at Visit 1 (Screening).\n\n        Exclusion Criteria:\n\n          -  Pregnant or breast feeding mothers\n\n          -  Patients with conditions contraindicated for treatment\n\n          -  Patients with a history of clinically significant diseases\n\n          -  Patients who have a clinically significant renal disease\n\n          -  Patients with myocardial infarctions less than 6 months prior to study entry\n\n          -  Patients with recent (less than 1 year) history of NYHA Class III/IV left ventricular\n             failure.\n\n          -  Patients with narrow-angle glaucoma, symptomatic prostatic hyperplasia or\n             bladder-neck obstruction or urinary retention\n\n          -  Patients with a history of malignancy of any organ system\n\n          -  Patients who have had a COPD exacerbation that required treatment with antibiotics,\n             and/or systemic steroids (oral or intravenous) and/or hospitalization in the 6 weeks\n             prior to Screening\n\n          -  Patients who have had a respiratory tract infection within 6 weeks prior to Screening\n\n          -  Patients with any history of asthma."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02125734", 
            "org_study_id": "CQVA149ADE04", 
            "secondary_id": "2013-004223-37"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment sequence 1", 
                    "Treatment sequence 2"
                ], 
                "description": "QVA149 capsules 110/50 \u00b5g for inhalation via Concep-1-inhaler device, taken once a day", 
                "intervention_name": "QVA149", 
                "intervention_type": "Drug", 
                "other_name": "indacaterol maleate/glycoporromium bromide"
            }, 
            {
                "arm_group_label": [
                    "Treatment sequence 1", 
                    "Treatment sequence 2"
                ], 
                "description": "Tiotropium 18 \u00b5g capsules for inhalation via HandiHaler device taken once a day", 
                "intervention_name": "Tiotropium", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tiotropium"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "12203"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "13057"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bonn", 
                        "country": "Germany", 
                        "zip": "53119"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "zip": "60318"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Garmisch-Partenkirchen", 
                        "country": "Germany", 
                        "zip": "82467"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany", 
                        "zip": "30317"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ibbenb\u00fcren", 
                        "country": "Germany", 
                        "zip": "49477"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kassel", 
                        "country": "Germany", 
                        "zip": "34121"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00fcnchen", 
                        "country": "Germany", 
                        "zip": "80686"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00fcnster", 
                        "country": "Germany", 
                        "zip": "48147"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Neu Isenburg", 
                        "country": "Germany", 
                        "zip": "63263"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rheine", 
                        "country": "Germany", 
                        "zip": "48431"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Siegen", 
                        "country": "Germany", 
                        "zip": "57072"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Solingen", 
                        "country": "Germany", 
                        "zip": "42665"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sonneberg", 
                        "country": "Germany", 
                        "zip": "96515"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warendorf", 
                        "country": "Germany", 
                        "zip": "48231"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Multicenter, Open-label, Cross-over Study to Assess Lung Function and Patient Preference After a 4 Week Treatment Each With QVA149 vs. Tiotropium in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD) and Moderate to Severe Airflow Limitation Who Are on a Tiotropium Therapy (FAVOR Study)", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Bundesamt f\u00fcr Arzneimittel und Medizinprodukte", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in Forced Expiratory Volume in one second (FEV1) will be calculated as the volume of air forcibly exhaled in one second as measured by a spirometer at weeks 4 and 8 post treatment.", 
            "measure": "Cahnge in Forced Expiratory Volume in one second (FEV1) at 1 h post-inhalation", 
            "safety_issue": "No", 
            "time_frame": "week 4 and week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02125734"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Patient preference for a QVA149 or tiotropium treatment will be assessed after experiencing both treatment regimens.", 
            "measure": "Patient treatment preference", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}